Antipsychotics influence Toll-like receptor (TLR) expression and its relationship with cognitive functions in schizophrenia

Brain, Behavior, and Immunity

Volumn 62, Issue , 2017, Pages 256-264

  Kéri, Szabolcs ^a,b,c   Szabó, Csilla ^b   Kelemen, Oguz ^d  

^a BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cognitive functions; Monocytes; Regulatory T cells; Schizophrenia; Toll like receptors

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TRANSCRIPTION FACTOR FOXP3; BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; MALE; MONOCYTE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; POSITIVE SYNDROME; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR DENSITY; REGULATORY T LYMPHOCYTE; SCHIZOPHRENIA; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; COGNITION; DRUG EFFECT; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; HUMANS; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 85008157597     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.12.011     Document Type: Article

References (64)

1. Aas, M., Dazzan, P., Mondelli, V., Melle, I., Murray, R.M., Pariante, C.M., A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front. Psychiatry, 4, 2014, 182.
2. Aguirre, A., Maturana, C.J., Harcha, P.A., Saez, J.C., Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediators Inflamm., 2013, 2013, 893521.
3. Akira, S., Takeda, K., Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004), 499–511.
4. Bora, E., Pantelis, C., Meta-analysis of cognitive impairment in first-episode bipolar disorder: comparison with first-episode schizophrenia and healthy controls. Schizophr. Bull. 41 (2015), 1095–1104.
5. Castano-Rodriguez, N., Kaakoush, N.O., Mitchell, H.M., Pattern-recognition receptors and gastric cancer. Front. Immunol., 5, 2014, 336.
6. Chang, S.H., Chiang, S.Y., Chiu, C.C., Tsai, C.C., Tsai, H.H., Huang, C.Y., Hsu, T.C., Tzang, B.S., Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res. 187 (2011), 341–346.
7. Chen, M.L., Tsai, T.C., Lin, Y.Y., Tsai, Y.M., Wang, L.K., Lee, M.C., Tsai, F.M., Antipsychotic drugs suppress the AKT/NF-kappaB pathway and regulate the differentiation of T-cell subsets. Immunol. Lett. 140 (2011), 81–91.
8. Chen, M.L., Tsai, T.C., Wang, L.K., Lin, Y.Y., Tsai, Y.M., Lee, M.C., Tsai, F.M., Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-alpha-directed cell apoptosis in neutrophils. Int. Immunopharmacol. 12 (2012), 197–204.
9. Chertkow, Y., Weinreb, O., Youdim, M.B., Silver, H., Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007), 1356–1362.
10. Constantinos, Z., Eleni, P., Goulas, A., Iakovidou-Kritsi, Z., Olanzapine: evaluation of the in vivo cytogenetic effect. Hum. Psychopharmacol. 30 (2015), 189–192.
11. Crisafulli, C., Drago, A., Calabro, M., Spina, E., Serretti, A., A molecular pathway analysis informs the genetic background at risk for schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 59 (2015), 21–30.
12. DeLisi, L.E., Crow, T.J., Is schizophrenia a viral or immunologic disorder?. Psychiatr. Clin. North Am. 9 (1986), 115–132.
13. Drzyzga, L., Obuchowicz, E., Marcinowska, A., Herman, Z.S., Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 20 (2006), 532–545.
14. Fernandez-Egea, E., Vertes, P.E., Flint, S.M., Turner, L., Mustafa, S., Hatton, A., Smith, K.G., Lyons, P.A., Bullmore, E.T., Peripheral immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. PLoS One, 11, 2016, e0155631.
15. Fieve, R.R., Blumenthal, B., Little, B., The relationship of atypical lymphocytes, phenothiazines, and schizophrenia. Arch. Gen. Psychiatry 15 (1966), 529–534.
16. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). 1996, American Psychiatric Press, Washington, D.C.
17. Frodl, T., Amico, F., Is there an association between peripheral immune markers and structural/functional neuroimaging findings?. Prog. Neuropsychopharmacol. Biol. Psychiatry 48 (2014), 295–303.
18. Ganguli, R., Brar, J.S., Rabin, B.S., Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv. Rev. Psychiatry 2 (1994), 70–83.
19. Garcia-Bueno, B., Gasso, P., MacDowell, K.S., Callado, L.F., Mas, S., Bernardo, M., Lafuente, A., Meana, J.J., Leza, J.C., Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. J. Psychiatry Neurosci. 41 (2016), E46–E55.
20. Garcia Bueno, B., Caso, J.R., Madrigal, J.L., Leza, J.C., Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases. Neurosci. Biobehav. Rev. 64 (2016), 134–147.
21. Girgis, R.R., Kumar, S.S., Brown, A.S., The cytokine model of schizophrenia: emerging therapeutic strategies. Biol. Psychiatry 75 (2014), 292–299.
22. Gold, J.M., Dickinson, D., “Generalized cognitive deficit” in schizophrenia: overused or underappreciated?. Schizophr. Bull. 39 (2013), 263–265.
23. Gold, J.M., Queern, C., Iannone, V.N., Buchanan, R.W., Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am. J. Psychiatry 156 (1999), 1944–1950.
24. Goldberg, T.E., Goldman, R.S., Burdick, K.E., Malhotra, A.K., Lencz, T., Patel, R.C., Woerner, M.G., Schooler, N.R., Kane, J.M., Robinson, D.G., Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 64 (2007), 1115–1122.
25. Hanke, M.L., Kielian, T., Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin. Sci. (Lond) 121 (2011), 367–387.
26. Hayward, J.H., Lee, S.J., A decade of research on TLR2 discovering its pivotal role in glial activation and neuroinflammation in neurodegenerative diseases. Exp. Neurobiol. 23 (2014), 138–147.
27. Juhasz, L.Z., Kemeny, K., Linka, E., Santha, J., Bartko, G., The use of RBANS test (Repeatable Battery for the Assessment of Neuropsychological Status) in neurocognitive testing of patients suffering from schizophrenia and dementia. Ideggyogy. Sz. 56 (2003), 303–308.
28. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
29. Keefe, R.S., Harvey, P.D., Cognitive impairment in schizophrenia. Handb. Exp. Pharmacol., 2012, 11–37.
30. Kenney, M.J., Ganta, C.K., Autonomic nervous system and immune system interactions. Compr. Physiol. 4 (2014), 1177–1200.
31. Keri, S., Szabo, C., Kelemen, O., Expression of Toll-Like Receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder. Brain Behav. Immun. 40 (2014), 235–243.
32. Khandaker, G.M., Cousins, L., Deakin, J., Lennox, B.R., Yolken, R., Jones, P.B., Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2 (2015), 258–270.
33. Kraepelin, E., Psychiatrie: Ein Lehrbuch für Studirende und Aerzte. 1899, Verlag Von Johann Ambrosius Bartil, Leipzig.
34. Leboyer, M., Oliveira, J., Tamouza, R., Groc, L., Is it time for immunopsychiatry in psychotic disorders?. Psychopharmacology 233 (2016), 1651–1660.
35. Leifer, C.A., McConkey, C., Li, S., Chassaing, B., Gewirtz, A.T., Ley, R.E., Linking genetic variation in human Toll-like receptor 5 genes to the gut microbiome's potential to cause inflammation. Immunol. Lett. 162 (2014), 3–9.
36. Maino, K., Gruber, R., Riedel, M., Seitz, N., Schwarz, M., Muller, N., T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 152 (2007), 173–180.
37. Matsumoto, A., Ohta, N., Goto, Y., Kashiwa, Y., Yamamoto, S., Fujino, Y., Haloperidol suppresses murine dendritic cell maturation and priming of the T helper 1-type immune response. Anesth. Analg. 120 (2015), 895–902.
38. McKernan, D.P., Dennison, U., Gaszner, G., Cryan, J.F., Dinan, T.G., Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl. Psychiatry, 1, 2011, e36.
39. Muller, N., Ackenheil, M., Hofschuster, E., Mempel, W., Eckstein, R., Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res. 37 (1991), 147–160.
40. Muller, N., Riedel, M., Gruber, R., Ackenheil, M., Schwarz, M.J., The immune system and schizophrenia. An integrative view. Ann. N. Y. Acad. Sci. 917 (2000), 456–467.
41. Muller, N., Wagner, J.K., Krause, D., Weidinger, E., Wildenauer, A., Obermeier, M., Dehning, S., Gruber, R., Schwarz, M.J., Impaired monocyte activation in schizophrenia. Psychiatry Res. 198 (2012), 341–346.
42. Nielsen, R.E., Levander, S., Kjaersdam Telleus, G., Jensen, S.O., Ostergaard Christensen, T., Leucht, S., Second-generation antipsychotic effect on cognition in patients with schizophrenia – a meta-analysis of randomized clinical trials. Acta Psychiatr. Scand. 131 (2015), 185–196.
43. Oberg, H.H., Juricke, M., Kabelitz, D., Wesch, D., Regulation of T cell activation by TLR ligands. Eur. J. Cell Biol. 90 (2011), 582–592.
44. Okun, E., Griffioen, K.J., Mattson, M.P., Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 34 (2011), 269–281.
45. Oliphant, C.J., Barlow, J.L., McKenzie, A.N., Insights into the initiation of type 2 immune responses. Immunology 134 (2011), 378–385.
46. Park, S.J., Lee, J.Y., Kim, S.J., Choi, S.Y., Yune, T.Y., Ryu, J.H., Toll-like receptor-2 deficiency induces schizophrenia-like behaviors in mice. Sci. Rep., 5, 2015, 8502.
47. Pearlson, G.D., Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. Annu. Rev. Clin. Psychol. 11 (2015), 251–281.
48. Qian, C., Cao, X., Regulation of Toll-like receptor signaling pathways in innate immune responses. Ann. N. Y. Acad. Sci. 1283 (2013), 67–74.
49. Reynolds, J.M., Dong, C., Toll-like receptor regulation of effector T lymphocyte function. Trends Immunol. 34 (2013), 511–519.
50. Richard, K.L., Filali, M., Prefontaine, P., Rivest, S., Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1–42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 28 (2008), 5784–5793.
51. Sarkar, C., Basu, B., Chakroborty, D., Dasgupta, P.S., Basu, S., The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24 (2010), 525–528.
52. Schwarz, M.J., Chiang, S., Muller, N., Ackenheil, M., T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 15 (2001), 340–370.
53. Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Schizophrenia Working Group of the Psychiatric Genomics, C., Daly, M.J., Carroll, M.C., Stevens, B., McCarroll, S.A., Schizophrenia risk from complex variation of complement component 4. Nature 530 (2016), 177–183.
54. Singh, B., Chaudhuri, T.K., Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res. 216 (2014), 277–285.
55. Sparkman, N.L., Johnson, R.W., Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. NeuroImmunoModulation 15 (2008), 323–330.
56. Sperner-Unterweger, B., Fuchs, D., Schizophrenia and psychoneuroimmunology: an integrative view. Curr. Opin. Psychiatry 28 (2015), 201–206.
57. Stefanovic, V., Mihajlovic, G., Nenadovic, M., Dejanovic, S.D., Borovcanin, M., Trajkovic, G., The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia. Vojnosanit. Pregl. 72 (2015), 1085–1092.
58. Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., Werge, T., Pietilainen, O.P., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Borglum, A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller, H.J., Giegling, I., Rasmussen, H.B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J.M., Magnusdottir, B.B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J.R., Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeney, L.A., Genetic, R., Outcome in, P., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., Yoon, J.L., Shianna, K.V., Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nothen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D.B., Stefansson, K., Collier, D.A., Common variants conferring risk of schizophrenia. Nature 460 (2009), 744–747.
59. Szoke, A., Trandafir, A., Dupont, M.E., Meary, A., Schurhoff, F., Leboyer, M., Longitudinal studies of cognition in schizophrenia: meta-analysis. Br. J. Psychiatry 192 (2008), 248–257.
60. Tan, H.Y., Callicott, J.H., Weinberger, D.R., Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn. Neuropsychiatry 14 (2009), 277–298.
61. Tourjman, V., Kouassi, E., Koue, M.E., Rocchetti, M., Fortin-Fournier, S., Fusar-Poli, P., Potvin, S., Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 151 (2013), 43–47.
62. Trotta, T., Porro, C., Calvello, R., Panaro, M.A., Biological role of Toll-like receptor-4 in the brain. J. Neuroimmunol. 268 (2014), 1–12.
63. Venkatasubramanian, G., Debnath, M., The TRIPS (Toll-like receptors in immuno-inflammatory pathogenesis) Hypothesis: a novel postulate to understand schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 44 (2013), 301–311.
64. Wieck, A., Grassi-Oliveira, R., do Prado, C.H., Viola, T.W., Petersen, L.E., Porto, B., Teixeira, A.L., Bauer, M.E., Toll-like receptor expression and function in type I bipolar disorder. Brain Behav. Immun. 54 (2016), 110–121.